Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Design, recruitment and baseline characteristics of the LENS trial.

LENS Collaborative Group None., (2024), Diabet Med, 41

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.

Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk None. and Cholesterol Treatment Trialists’ (CTT) Collaboration None., (2024), Lancet Diabetes Endocrinol, 12, 306 - 319

Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.

Mayne KJ. et al, (2024), J Am Soc Nephrol, 35, 202 - 215

Empagliflozin in Patients with Chronic Kidney Disease.

The EMPA-KIDNEY Collaborative Group None. et al, (2023), N Engl J Med, 388, 117 - 127

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.

Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329

Load More